Free Trial

Guggenheim Has Lowered Expectations for Absci (NASDAQ:ABSI) Stock Price

Absci logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Guggenheim lowered its Absci price target from $15 to $14 but maintained a Buy rating; the new target implies about 81% upside from the stock’s current price.
  • Analyst sentiment is broadly positive: 11 analysts rate the stock Buy and one rates it Sell, with a consensus “Moderate Buy” rating and a $14.90 average price target.
  • Absci reported quarterly EPS in line with estimates at a loss of $0.19 per share, while revenue of $0.30 million came in below the $0.66 million consensus estimate; shares opened down 8.5% at $7.73 on Monday.
  • Interested in Absci? Here are five stocks we like better.

Absci (NASDAQ:ABSI - Get Free Report) had its price objective lowered by Guggenheim from $15.00 to $14.00 in a report issued on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price objective would suggest a potential upside of 81.14% from the stock's current price.

Several other brokerages have also recently commented on ABSI. KeyCorp boosted their price target on Absci from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, October 16th. HC Wainwright restated a "buy" rating on shares of Absci in a report on Tuesday, October 20th. Wall Street Zen upgraded Absci from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Absci in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Absci from $14.00 to $15.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.90.

View Our Latest Stock Analysis on ABSI

Absci Stock Down 8.5%

ABSI stock opened at $7.73 on Monday. The stock has a market capitalization of $1.33 billion, a P/E ratio of -10.18 and a beta of 2.22. Absci has a 52 week low of $2.24 and a 52 week high of $12.54. The firm has a 50-day simple moving average of $9.65 and a 200-day simple moving average of $6.81.

Absci (NASDAQ:ABSI - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). Absci had a negative return on equity of 61.60% and a negative net margin of 8,451.31%. The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.66 million. On average, analysts expect that Absci will post -0.76 earnings per share for the current year.

Hedge Funds Weigh In On Absci

A number of institutional investors have recently bought and sold shares of ABSI. Parkman Healthcare Partners LLC purchased a new stake in Absci in the second quarter valued at $10,366,000. Siren L.L.C. acquired a new position in shares of Absci in the 1st quarter valued at $5,400,000. Bank of America Corp DE acquired a new position in shares of Absci in the 2nd quarter valued at $6,560,000. Deutsche Bank AG acquired a new position in shares of Absci in the 2nd quarter valued at $1,591,000. Finally, Artia Global Partners LP purchased a new position in shares of Absci during the 2nd quarter worth $5,383,000. 52.05% of the stock is owned by hedge funds and other institutional investors.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Featured Articles

Analyst Recommendations for Absci (NASDAQ:ABSI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Absci Right Now?

Before you consider Absci, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.

While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines